Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging, Phase 2b Study to Evaluate Efficacy and Safety of Tezepelumab for the Treatment of Chronic Spontaneous Urticaria

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

26 Feb 2024 Primary endpoint (Change from Baseline in Urticaria Activity Score over 7 days (UAS7) has not been met according to results presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
26 Feb 2024 Results of subgroup analysis assessing the effects of tezepelumab in a subgroup (anti-IgE naive) of CSU patients presented at the 2024 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
27 Apr 2023 According to an Amgen media release, top-line data from this study anticipated in mid-2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com